Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma

Journal of the American Veterinary Medical Association

Volumn 232, Issue 6, 2008, Pages 879-885

  Simon, Daniela ^a   Moreno, Sol Naranjo ^a   Hirschberger, Johannes ^b   Moritz, Andreas ^c   Kohn, Barbara ^d   Neumann, Stephan ^e   Jurina, Konrad ^f   Scharvogel, Stefan ^f   Schwedes, Claudia ^g   Reinacher, Manfred ^c   Beyerbach, Martin ^a   Nolte, Ingo ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g Small Animal Clinic Augsburg ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; MORTALITY; REMISSION; SURVIVAL; TIME; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; LYMPHOMA; MALE; NEOPLASM STAGING; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 41749098855     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.232.6.879     Document Type: Article

References (29)

1. Dorn CR, Taylor DO, Schneider R, et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318.
2. Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukaemia and lymphoma. Bibl Haematol 1970;36:403-415.
3. Dobson JM, Samuel S, Milstein H, et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002;43:240-246.
4. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990;66:480-490.
5. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7: 289-295.
6. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
7. Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1983;23:587-596.
8. Postorino NC, Susaneck SJ, Withrow SJ, et al. Single agent therapy with Adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989;25:221-225.
9. Mutsaers AJ, Glickman NW, DeNicola DB, et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 2002;220:1813-1817.
10. Hahn KA, Richardson RC, Teclaw RF, et al. Is maintenance chemotherapy appropriate for the management of canine lymphoma? J Vet Intern Med 1992;6:3-10.
11. Piek CJ, Rutteman GR, Teske E. Evaluation of the results of L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with lymphoma. Vet Q 1999;21:44-49.
12. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
13. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
14. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
15. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
16. Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin's lymphoma. In: DeVita DT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2001;2256-2303.
17. Owen LN. TNM classification of tumors in domestic animals. Geneva: World Health Organization, 1980;46-47.
18. Culmsee K, Simon D, Mischke R, et al. Possibilities of flow cytometric analysis for immunophenotypie characterization of canine lymphoma. J Vet Med A Physiol Pathol Clin Med 2001;48:199-206.
19. Veterinary Co-Operative Oncology Group. Veterinary Co-Operative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
20. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
21. Ruslander DA, Gebhard DH, Tompkins MB, et al. Immunophenotypie characterization of canine lymphoproliferative disorders. In Vivo 1997;11:169-172.
22. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997;210:512-516.
23. Myers NC III, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
24. Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multi-centric lymphosarcoma. J Small Anim Pract 2001;42:377-384.
25. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA / LVP. J Am Anim Hosp Assoc 2000;36:395-403.
26. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.
27. Cotter SM, Goldstein MA. Treatment of lymphoma and leukaemia with cyclophosphamide, vincristine, and prednisone. I: treatment of dogs. J Am Anim Hosp Assoc 1987;19:159-165.
28. Glasgow RE, Magid DJ, Beck A, et al. Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care 2005;43:551-557.
29. Yessaian A, Mendivil AA, Brewster WR. Population characteristics in cervical cancer trials: search for external validity. Am J Obstet Gynecol 2005;192:407-413.